Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance

References

• Ballesteros S, Ramón MF, Iturralde MJ, Martínez-Arrieta R. (2006). Natural sources of drugs of abuse: magic mushrooms. In: Cole SM, ed. New research on street drugs. New York, 167–186.
   Google Scholar
• Barbosa J, Faria J, Queiros O, et al. (2016). Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab Rev 48:577–592.
   PubMed Web of Science ®Google Scholar
• Blaschko H, Levine WG. (1960). Enzymatic oxidation of psilocine and other hydroxyindoles. Biochem Pharmacol 3:168–169.
   Web of Science ®Google Scholar
• Chan RHA, Mendelson JE. (2014) Chapter seventeen – Hallucinogens. In: The effects of drug abuse on the human nervous system. Boston: Academic Press, 533–552.
   Google Scholar
• Cody JT. (2008). Chapter 4 Hallucinogens. In: Bogusz MJ, ed. Handbook of analytical separations. Amsterdam, Netherlands: Elsevier Science B.V., 175–201.
   Google Scholar
• Creese I, Burt DR, Synder SH. (1975). The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 17:1715–1719.
   PubMed Web of Science ®Google Scholar
• de Veen BT, Schellekens AF, Verheij MM, Homberg JR. (2016). Psilocybin for treating substance use disorders? Expert Rev Neurother 17:203–212.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. (2014). Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. Curr Topics Med Chem 14:200–206.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2014). Metabolomics of drugs of abuse: a more realistic view of the toxicological complexity. Bioanalysis 6:3155–3159.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2015). Metabolomics of cocaine: implications in toxicity. Toxicol Mech Methods 25:494–500.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016a). Metabolomics of Delta9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev 48:80–87.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016b). Metabolomics of delta(9)-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev 48:80–87.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016c). Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metab Rev 48:568–576.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016d). Oxidative and non-oxidative metabolomics of ethanol. Curr Drug Metab 17:327–335.
   PubMed Web of Science ®Google Scholar
• Eivindvik K, Rasmussen KE, Sund RB. (1989). Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon. Acta Pharm Nord 1:295–302.
   PubMedGoogle Scholar
• Fowler JS, Volkow ND, Wang GJ, et al. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736.
   PubMed Web of Science ®Google Scholar
• Franke AA, Custer LJ, Wilkens LR, et al. (2002). Liquid chromatographic-photodiode array mass spectrometric analysis of dietary phytoestrogens from human urine and blood. J Chromatogr B Analyt Technol Biomed Life Sci 777:45–59.
   PubMed Web of Science ®Google Scholar
• Freedman DX, Gottlieb R, Lovell RA. (1970). Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharm 19:1181–1188.
   Web of Science ®Google Scholar
• Grieshaber AF, Moore KA, Levine B. (2001). The detection of psilocin in human urine. J Forensic Sci 46:627–630.
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78.
   PubMed Web of Science ®Google Scholar
• Guzmán G. (2008). Hallucinogenic mushrooms in Mexico: an overview. Econ Bot 62:404–412.
   Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61:364–381.
   PubMed Web of Science ®Google Scholar
• Halpern JH. (2004). Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131–138.
   PubMed Web of Science ®Google Scholar
• Hasler F, Bourquin D, Brenneisen R, et al. (1997). Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72:175–184.
   PubMedGoogle Scholar
• Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal 30:331–339.
   PubMed Web of Science ®Google Scholar
• Helsley S, Fiorella D, Rabin RA, Winter JC. (1998). A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus. Prog Neuro-Psychopharmacol Biol Psychiatry 22:649–663.
   PubMed Web of Science ®Google Scholar
• Hendrie C, Pickles A. (2016). Psilocybin: panacea or placebo? Lancet Psychiatry 3:805–806.
   PubMed Web of Science ®Google Scholar
• Hofmann A. (1968) Psychomimetic agents. In: Burger A, ed. Drugs affecting the central nervous system, medicinal research series 2. New York: Dekker, 169–235.
   Google Scholar
• Hofmann A, Heim R, Brack A, Kobel H. (1958). Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim. Experientia 14:107–109.
   PubMedGoogle Scholar
• Hofmann A, Heim R, Brack A, et al. (1959). Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helvetica Chimica Acta 42:1557–1572.
   Web of Science ®Google Scholar
• Hopf A, Eckert H. (1974). Distribution patterns of 14-C-psilocin in the brains of various animals. Act Nerv Super 16:64–66.
   PubMedGoogle Scholar
• Horita A. (1963). Some biochemical studies on psilocybin and psilogin. J Neuropsychiatry 4:270–273.
   PubMed Web of Science ®Google Scholar
• Horita A, Weber LJ. (1961a). The enzymic dephosphorylation and oxidation of psilocybin and pscilocin by mammalian tissue homogenates. Biochem Pharmacol 7:47–54.
   PubMed Web of Science ®Google Scholar
• Horita A, Weber LJ. (1961b). The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol 7:47–54.
   PubMed Web of Science ®Google Scholar
• Horita A, Weber LJ. (1962). Dephosphorylation of psilocybin in the intact mouse. Toxicol Appl Pharmacol 4:730–737.
   PubMed Web of Science ®Google Scholar
• Isbell H. (1959). Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1:29–38.
   PubMed Web of Science ®Google Scholar
• Isbell H, Wolbach AB, Wikler A, Miner EJ. (1961). Cross tolerance between LSD and psilocybin. Psychopharmacologia 2:147–159.
   PubMed Web of Science ®Google Scholar
• Jensen N, Gartz J, Laatsch H. (2006). Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens. Planta Medica 72:665–666.
   PubMed Web of Science ®Google Scholar
• Johnson M, Richards W, Griffiths R. (2008). Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxford) 22:603–620.
   PubMed Web of Science ®Google Scholar
• Kalberer F, Kreis W, Rutschmann J. (1962). The fate of psilocin in the rat. Biochem Pharmacol 11:261–269.
   PubMed Web of Science ®Google Scholar
• Kamata T, Katagi M, Kamata HT, et al. (2006). Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab Dispos 34:281–287.
   PubMed Web of Science ®Google Scholar
• Katzung BG, Masters SB, Trevor AJ. (2012). Basic and clinical pharmacology. New York: McGraw-Hill.
   Google Scholar
• Kovacic P. (2009). Unifying electron transfer mechanism for psilocybin and psilocin. Medical Hypotheses 73:626.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Cooksy AL. (2005). Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med Hypotheses 64:357–366.
   PubMed Web of Science ®Google Scholar
• Lim TH, Wasywich CA, Ruygrok PN. (2012). A fatal case of 'magic mushroom' ingestion in a heart transplant recipient. Intern Med J 42:1268–1269.
   PubMed Web of Science ®Google Scholar
• Lindenblatt H, Kramer E, Holzmann-Erens P, et al. (1998). Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction. J Chromatogr B Biomed Sci Appl 709:255–263.
   PubMed Web of Science ®Google Scholar
• Mahmood ZA, Ahmed SW, Azhar I, et al. (2010). Bioactive alkaloids produced by fungi. I. Updates on alkaloids from the species of the genera Boletus, Fusarium and psilocybe. Pak J Pharm Sci 23:349–357.
   PubMed Web of Science ®Google Scholar
• Manevski N, Kurkela M, Hoglund C, et al. (2010). Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos 38:386–395.
   PubMed Web of Science ®Google Scholar
• Martin R, Schurenkamp J, Gasse A, et al. (2013a). Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. Int J Legal Med 127:593–601.
   PubMed Web of Science ®Google Scholar
• Martin R, Schürenkamp J, Gasse A, et al. (2013b). Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. Int J Legal Med 127:593–601.
   PubMed Web of Science ®Google Scholar
• Martin R, Schurenkamp J, Pfeiffer H, Kohler H. (2012). A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. Int J Legal Med 126:845–849.
   PubMed Web of Science ®Google Scholar
• Martin R, Schurenkamp J, Pfeiffer H, et al. (2014). Synthesis, hydrolysis and stability of psilocin glucuronide. Forensic Sci Int 237:1–6.
   PubMed Web of Science ®Google Scholar
• McKenna DJ, Repke DB, Lo L, Peroutka SJ. (1990). Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29:193–198.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–1740.
   PubMed Web of Science ®Google Scholar
• Muller K, Puschel K, Iwersen-Bergmann S. (2013). Suicide under the influence of “magic mushrooms”. Arch Fur Kriminol 231:193–198.
   PubMedGoogle Scholar
• Nichols DE. (2004). Hallucinogens. Pharmacol Ther 101:131–181.
   PubMed Web of Science ®Google Scholar
• Nichols DE. (2016). Psychedelics. Pharmacol Rev 68:264–355.
   PubMed Web of Science ®Google Scholar
• Osmond H. (1957). A review of the clinical effects of psychotomimetic agents. Ann New York Acad Sci 66:418–434.
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, Emrich HM. (2002). The pharmacology of psilocybin. Addict Biol 7:357–364.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard S, Sannes E, Rasmussen KE, Tonnesen F. (1997). Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis. J Chromatogr Biomed Sci Appl 694:375–381.
   PubMed Web of Science ®Google Scholar
• Sewell RA, Halpern JH, Pope HG. Jr. (2006). Response of cluster headache to psilocybin and LSD. Neurology 66:1920–1922.
   PubMed Web of Science ®Google Scholar
• Shirota O, Hakamata W, Goda Y. (2003). Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of “magic mushroom”. J Nat Prod 66:885–887.
   PubMed Web of Science ®Google Scholar
• Shulgin AT. (1980). Profiles of psychedelic drugs. Psilocybin. J Psychedel Drugs 12:79
   PubMed Web of Science ®Google Scholar
• Sticht G, Kaferstein H. (2000). Detection of psilocin in body fluids. Forensic Sci Int 113:403–407.
   PubMed Web of Science ®Google Scholar
• Tittarelli R, Mannocchi G, Pantano F, Romolo FS. (2015). Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol 13:26–46.
   PubMed Web of Science ®Google Scholar
• Tyls F, Palenicek T, Horacek J. (2014). Psilocybin–summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24:342–356.
   PubMed Web of Science ®Google Scholar
• van Amsterdam J, Opperhuizen A, van den Brink W. (2011). Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol 59:423–429.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vontobel P, Hell D, Leenders KL. (1999). 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man – a PET study with [11C]raclopride. Neuropsychopharmacology 20:424–433.
   PubMed Web of Science ®Google Scholar
• Wolbach AB, Jr., Miner EJ, Isbell H. (1962). Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 3:219–223.
   PubMed Web of Science ®Google Scholar